- Company
- Olumiant may land to treat alopecia areata in KOR this year
- by Eo, Yun-Ho Feb 9, 2023 05:49am
- The JAK inhibitor ‘Olumiant’ may be prescribed to treat hair loss in Korea within the year. According to industry sources, the Ministry of Food and Drug Safety is conducting a review on expanding the indication of Lilly Korea’s JAK inhibitor Olumiant (baricitinib) to severe alopecia areata in Korea. The company may receive the final ma
- Company
- Entresto’s sales exceeded KRW 40 billion last year
- by Feb 8, 2023 05:53am
- Sales of Novartis Korea’s chronic heart failure treatment ‘Entresto’ has exceeded KRW 40 billion 6 years into its release. According to market research institution UBIST on the 7th, Entresto’s outpatient prescription sales had recorded KRW 40.6 billion last year. This is a 26% increase from the KRW 32.3 billion it had recorded the pr
- Company
- Huonslab is speeding up the development of Prolia biosimilar
- by Lee, Seok-Jun Feb 8, 2023 05:53am
- Huonslab announced on the 7th that it has confirmed that the HLB3-013 biosimilar under development is equally effective in non-clinical animal efficacy tests compared to the original Prolia. This is the result of an osteoporosis-causing model mouse at an overseas CRO institution (BioMedCore, Greece). When the original and HLB3-013 were treate
- Company
- Prescription of Celltrion’s Takeda drugs fall for 2 yrs
- by Kim, Jin-Gu Feb 8, 2023 05:53am
- Prescription performance of the 3 major chronic disease treatments that Celltrion Pharm acquired from Takeda Pharmaceutical had fallen for 2 consecutive years since their acquisition. The ‘Nesina’ series, which account for the most proportion of sales among the acquired products, recorded KRW 28.2 billion in sales last year, recording a dow
- Company
- The first reverse growth of NOAC worth 230 billion won
- by Jung, Sae-Im Feb 8, 2023 05:53am
- The NOAC market, which is worth 230 billion won, fell for the first time last year. This is because the generic market for some items was opened and drug prices were cut. Generics, which competed with the original "Xarelto," secured a market worth 9 billion won last year. According to Ubist, a pharmaceutical market research firm on the 8th,
- Company
- Dong-A Forxiga loses the patent dispute
- by Kim, Jin-Gu Feb 7, 2023 05:48am
- A new method of avoiding material patents virtually fails the 'prodrug' strategy, which was drawing attention. Dong-A ST lost the Forxiga patent dispute alone. Dong-A ST pushed ahead with the release of Forxiga's late drug, Dapapro, on the basis of its victory in the first trial, but the ruling put considerable pressure on sales. ◆ Dong-A
- Company
- SGLT-2 Market ↑3x in 3 years
- by Jung, Sae-Im Feb 7, 2023 05:47am
- The domestic SGLT-2 inhibitor outpatient prescription market has grown to 170 billion won. It has more than tripled in the past three years. It has been about 10 years since SGLT-2 inhibitors entered Korea. This year, a major change is expected as a number of "Forxiga" generics leading the market are released and new domestic SGLT-2 inhibitor
- Company
- Does the Xospata dosing cycle limit disappear?
- by Eo, Yun-Ho Feb 6, 2023 05:51am
- The new leukemia drug Xospata is aiming to expand insurance benefit standards again. According to related industries, Astellas Pharmaceutical Korea submitted an application to expand the salary of Acute Myeloid Leukemia treatment Xospata at the end of last year and is currently discussing the schedule for the cancer disease review committee
- Company
- Mavyret occupies 85% of HCV market...sales fall 36% in 3 yrs
- by Kim, Jin-Gu Feb 6, 2023 05:51am
- Abbvie’s Mavyret has dominated the oral hepatitis C treatment market. Last year the drug increased its market share to 85%. Despite this increase in market share, the drug’s prescription performance fell 36% over the past 3 years. The analysis is that the absolute size of the Hepatitis C treatment market, which has a limited number of p
- Company
- EXKIVITY, PO lung cancer treatment, is released
- by Jung, Sae-Im Feb 3, 2023 08:51am
- Differences between oral medication and long-lasting effects "Further study needed to find suitable patient population" The second new drug targeting EGFR mutations, which are rare in non-small cell lung cancer, has been released in Korea. Takeda Pharmaceutical's Exkivity is expected to compete with oral drugs and long reaction duration. T
